Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 06 - 29 save search
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.08%
H: 0.66%
C: -0.95%
treatment phase 2 trial lupus enroll
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
HRMY | $29.19 -1.98% -2.02% 330K
|
Health Technology
|
| O: 0.24%
H: 1.81%
C: -0.92%
phase 2 trial bioscience
VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19
Published: 2021-06-29 (Crawled : 12:00) - vbivaccines.com
VBIV | $0.591 -4.68% -4.91% 370K
|
Health Technology
|
| O: 2.59%
H: 4.76%
C: -9.58%
covid phase 1 positive vaccine phase 2 phase 3 covid-19
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease
Published: 2021-06-29 (Crawled : 12:00) - prnewswire.com
PTN | $1.9 1.6% -2.11% 230K
|
Health Technology
|
| O: 7.22%
H: 15.17%
C: 15.17%
dry eye disease treatment fda phase 2 eye positive eye disease
Yamana Gold Provides Notice of Second Quarter 2021 Results and Notice Relating to Updates on Phase 2 Expansion at Jacobina and Construction of the Odyssey Project and Wasamac Project
Published: 2021-06-29 (Crawled : 12:00) - globenewswire.com
AUY | $5.85 -0.68% -0.51% 0
|
Non-Energy Minerals
|
| O: -1.65%
H: 1.43%
C: 0.24%
phase 2 expansion results
DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD
Published: 2021-06-29 (Crawled : 12:00) - biospace.com/
DMAC | News | $2.58 8.86% 8.14% 41K
|
Health Technology
|
| O: -26.78%
H: 0.76%
C: -9.71%
phase 2 positive results
IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial
Published: 2021-06-29 (Crawled : 11:00) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: -0.78%
H: 4.26%
C: -1.68%
phase 1 collaboration trial phase 2 phase 3
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
Published: 2021-06-29 (Crawled : 06:00) - globenewswire.com
ADXN | $22.8 0.89% 0.88% 16K
|
Health Technology
|
| O: 1.4%
H: 2.07%
C: -0.56%
disease phase 2 parkinson phase 2b skin
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.